Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease

NCT03705234 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT03705234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03705234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease
Lead sponsor
University of Oxford
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 30, 2018
Completion date
December 31, 2049
Enrollment
16,124 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic cardiovascular disease